Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma

Trial Profile

Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Tretinoin (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 13 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Oct 2017.
    • 01 Aug 2017 Planned initiation date changed from 1 Aug 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top